Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Ophthalmol. Nov 12, 2014; 4(4): 92-112
Published online Nov 12, 2014. doi: 10.5318/wjo.v4.i4.92
Pathogenesis, prevention, diagnosis and management of retinal vein occlusion
Shay Keren, Anat Loewenstein, Gabriel Coscas
Shay Keren, Anat Loewenstein, Ophthalmology Department, Tel-aviv Medical Center, Tel-Aviv 64239, Israel
Gabriel Coscas, Hôpital Intercommunal de Créteil, Service d’Ophtalmologie, 94010 Creteil, France
Author contributions: All authors contributed to this manuscript.
Correspondence to: Shay Keren, MD, Ophthalmology Department, Tel-Aviv Medical Center, 6th Weitzman Street, Tel-Aviv 64239, Israel.
Telephone: +972-3-6973408 Fax: +972-3-6973870
Received: May 30, 2014
Revised: August 26, 2014
Accepted: September 16, 2014
Published online: November 12, 2014
Core Tip

Core tip: Retinal vein occlusion (RVO) is the second vascular retinal cause of visual loss and is defined by the occlusion of a retinal vein. The diagnosis of the disease is easier with the common use of spectral domain optical coherence tomography and fluorescein angiography. The treatment options for RVO, has changed over the past years with the introduction of the intravitreal injections of dexamethasone (Ozurdex), bevacizumab (Avastin), ranibizumab (Lucentis) and aflibercept (EYLEA). This manuscript is a review of current literature about RVO and provides tools and knowledge to guide the physician in treating patients.